Thumbnail Image
Publication

FDA Enforcement Actions Against False and Misleading Prescription Drug Advertisements Declined in 2003

House Committee on Government Reform
; 
Special Investigations Division
Abstract
The Special Investigations Division of the House Committee on Government Reform investigated a significant drop in FDA enforcement actions against false and misleading drug advertising during the first two years of the Bush Administration. Despite FDA Commissioner Mark McClellan's promise of more aggressive enforcement in 2003, the report states enforcement actions continued to decline that year, and delays in responding to false and misleading advertisements increased. The division suggest a contrast between the Commissioner's commitment and the actual enforcement trends at the FDA.
Date
2004-01-29
Document Type
House Minority Staff Report
Serial Number
Document Length
8 pages
Congress
108
Show all metadata
Files
Thumbnail Image
2004-01-29_R-FDA_Enforcement_Actions_Against_False+Misleading_Prescription_Drug_Advertisements-108C.pdf
Adobe PDF, 191.75 KB
URI
https://hdl.handle.net/20.500.14300/1000
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
321: Regulation of Drug Industry, Medical Devices, and Clinical Labs
Related Hearings
Press Releases and Contextual Information
https://web.archive.org/web/20051024194711/http://www.democrats.reform.house.gov/story.asp?ID=440&Issue=Prescription+Drugs
Collections
House Oversight Committee